At Chimerix, we’re on a mission to discover and develop much-needed medicines that protect immunocompromised patients from potentially devastating viral infections. For people with weakened immune systems and patients undergoing bone marrow transplants, common viruses can quickly become life-threatening.
We believe it is possible to treat or prevent life-threatening viral infections caused by adenovirus, CMV and BK virus in vulnerable stem cell transplant recipients. Our proprietary lipid conjugate technology has led us to two product candidates currently showing great potential: brincidofovir (CMX001) and CMX157, which was licensed to ContraVir Pharmaceuticals. Brincidofovir, a clinical-stage lipid conjugate nucleotide analog, has demonstrated broad-spectrum antiviral activity against the most important dsDNA viruses that affect humans, including adenovirus, the virus that causes smallpox (Variola) and cytomegalovirus.
Chimerix also conducts targeted screening of its Chemical Library for other compounds active against viruses with unmet medical need. Recent success in screening and preclinical development has resulted in a clinical candidate for prevention and treatment of norovirus.